The gut microbiome: role in causing and detecting colorectal cancer
Speaking from the 2018 National Cancer Research Institute (NCRI) Cancer Conference, held in Glasgow, UK, Paul O'Toole, PhD, from the University College Cork, Cork, Ireland, discusses the role of the gut microbiome as a promising and targetable risk factor for colorectal cancer (CRC). Prof. O'Toole not only highlights the microbial community within the gut as a potential diagnostic tool for CRC, but also as a modifiable modulator of cancer immunotherapy.
Видео The gut microbiome: role in causing and detecting colorectal cancer канала VJOncology
Видео The gut microbiome: role in causing and detecting colorectal cancer канала VJOncology
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
![4-year MonarchE results: increasing benefits with abemaciclib + ET for ER+/HER2- high-risk early BC](https://i.ytimg.com/vi/oJvZuVjOBJk/default.jpg)
![OPERA: contact X-ray brachytherapy in addition to CRT in organ preservation for rectal cancer](https://i.ytimg.com/vi/n6gpNKp66KA/default.jpg)
![AMBER: cobolimab monotherapy & in combination with PD-1 inhibitors nivolumab or dostarlimab](https://i.ytimg.com/vi/hN101PjDcZk/default.jpg)
![Real-world toxicities associated with lorlatinib in ALK+ NSCLC](https://i.ytimg.com/vi/OokKfNU8Ml4/default.jpg)
![What to do in patients with early-stage TNBC who have not achieved a pCR?](https://i.ytimg.com/vi/rEQ9vYDczrE/default.jpg)
![Current treatment recommendations and future directions for EGFR-mutant NSCLC](https://i.ytimg.com/vi/mp3apAnwjFc/default.jpg)
![Does every patient with localized muscle-invasive bladder cancer need a cystectomy?](https://i.ytimg.com/vi/ut81rE4V5uY/default.jpg)
![The future of immunotherapy in melanoma](https://i.ytimg.com/vi/x9chJq3Xd8k/default.jpg)
![Bias and microaggressions in healthcare](https://i.ytimg.com/vi/kPOEX66P-E0/default.jpg)
![Upcoming NSCLC trials in 2022: CheckMate 816 & KEYNOTE-091](https://i.ytimg.com/vi/YLoFH1sgamA/default.jpg)
![Exciting updates from ASCO 2022 in the anti-EGFR rechallenge space for colorectal cancer](https://i.ytimg.com/vi/XJYAdrXjDbA/default.jpg)
![Long-term outcomes of DSNB for cN0 penile cancer](https://i.ytimg.com/vi/IEa5rR7vPUs/default.jpg)
![Kidney cancer: post-surgery sorafenib](https://i.ytimg.com/vi/wc3gIwh93V0/default.jpg)
![Immunotherapy & local ablative therapy in mCRC with liver metastases](https://i.ytimg.com/vi/7ErQUUVhcMc/default.jpg)
![PET vs. MRI in re-irradiation for recurrent glioblastoma: insights from a Phase II trial](https://i.ytimg.com/vi/yZtqXuX4FtY/default.jpg)
![MiST5: niraparib and dostarlimab in relapsed malignant mesothelioma](https://i.ytimg.com/vi/OM7oPzU8We8/default.jpg)
![The role of dendritic cells in eliciting an anti—tumor immune response](https://i.ytimg.com/vi/3qr4qG_VOBs/default.jpg)
![Advances in the development of KRAS inhibitors](https://i.ytimg.com/vi/QtzC0IrX95o/default.jpg)
![NRG-HN002: chemoradiotherapy for p16-positive low-risk HPV-associated oropharyngeal carcinoma](https://i.ytimg.com/vi/jpj62lToaAc/default.jpg)
![Facial plastic surgery after skin cancer](https://i.ytimg.com/vi/xioV1vJ8APs/default.jpg)
![HER2DX and pCR in HER2-positive breast cancer: a combined analysis of 4 neoadjuvant studies](https://i.ytimg.com/vi/oumQTvTw1jo/default.jpg)